# FutuRx

> FutuRx is a VC fund in Ness Ziona backing Biotechnology and Biopharma. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Ness Ziona, Israel
- Total investments: 5
- Last investment: May 2021
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://futurx.co.il/

FutuRx is a VC fund in Ness Ziona focused on Biotechnology and Biopharma. FutuRx is the Israeli biotechnology accelerator that was established in 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development Corporation (JJDC) and Takeda Ventures Inc. following winning the tender of the Office of the Chief Scientist (OCS), Ministry of Economy, in Israel.The incubator willadvance new biotechnology products by identifying and nurturing early-stage life science innovation.FutuRx is located in the Weizmann Science Park in Ness Ziona (near the Weizmann Institute), Israel.

## Contacts

5 contacts available for FutuRx. Shizune tracks 1 team members at FutuRx. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/futurx?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 100% |
| Biopharma | 3 | 60% |
| Life Science | 3 | 60% |
| Therapeutics | 2 | 40% |
| Health Care | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 80% |
| Funding Round | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| KINNERET SAVITSKY | Chief Executive Officer | 0 | https://shizune.co/investors/profile/kinneret-savitsky |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Skip Therapeutics | Skip Therapeutics develops precision, RNA-based, treatments for rare genetic diseases. Millions of people worldwide are affected by thousands of rare genetic disorders, yet the limited patient populations, further divided by patient-specific mutations, have hampered the discovery of effective treatments. Recent developments in RNA-therapeuticsprovide an enlarged molecular toolkit that can be used quickly and affordably to repair damaged genes' ability to make proteins. Computational techniques could be used to help identify sub-patient populations that would be eligible for treatment with RNA-based therapeutics and match molecular therapy options across the large landscape of known disease-causing mutations. |  | Seed | May 01, 2021 |  |
| JAMM Therapeutics | JAMM Therapeutics is a drug discovery company developing small molecule modulators for the treatment of systemic lupus erythematosus (SLE).A family of cytokines known as type I IFNs exhibits antiviral, antiproliferative, and immunomodulatory functions. All type I IFNs function by attaching to the same receptor complex, which has the IFNAR1 andIFNAR2 subunits. IFNAR1 polyubiquitination, which instructs the internalized receptor for destruction in the lysosome, is one of the mechanisms regulating type I IFN activation. IFNAR1's K63-conjugated polyubiquitin chain can be disassembled by the cytoplasmic complex DUB, also known as BRISC (BRCC36 isopeptidase complex), which stabilizes IFNAR1 and encourages IFN-dependent reactions. Both in humans and mice, type I IFNs play a key role in the pathogenesis of SLE. When SLE is produced in BRISC-deficient mice, the mice show improved clinical functioning, reduced IFN responses, and protection against immunopathology linked to IFN. |  | Seed | May 01, 2020 |  |
| Protekt Therapeutics | ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019. | $4.1M |  | Nov 12, 2019 |  |
| Bsense Bio Therapeutics | Bsense Bio Therapeutics develops small molecules for the treatment of sensory hyperexcitability related disorders. Bsense pioneers a novel approach targeting multiple hyperexcitability-related mechanisms using a single compound, to achieve greater efficacy and safety. | $405K | Seed | Oct 01, 2018 |  |
| Ramino Bio | Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases.Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusivetechnology lowers the extra BCAA that is floating around. |  | Seed | Sep 01, 2018 |  |

5 of 5 investments shown.

## Co-investors
- [RMGP Biopharma Investment Fund](https://shizune.co/investors/profile/rmgp-biopharma-investment-fund) — VC Fund, 4 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 3 deals together
- [Takeda Ventures](https://shizune.co/investors/profile/takeda-ventures) — VC Fund, 3 deals together
- [Israel Innovation Authority](https://shizune.co/investors/profile/israel-innovation-authority) — VC Fund, 2 deals together
- [Johnson & Johnson Robotics and Digital Solutions](https://shizune.co/investors/profile/johnson-johnson-innovation) — VC Fund, 2 deals together
- [Bukwang Pharmaceutical Co](https://shizune.co/investors/profile/bukwang-pharmaceutical-co) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Middle East](https://shizune.co/investors/biotechnology-investors-middle-east)
- [Biotechnology VC Funds in Middle East](https://shizune.co/investors/biotechnology-vc-funds-middle-east)
- [Health Care VC Funds in Israel](https://shizune.co/investors/health-care-vc-funds-israel)
- [Biotech Investors in Middle East](https://shizune.co/investors/biotech-investors-middle-east)
- [Biotech VC Funds in Middle East](https://shizune.co/investors/biotech-vc-funds-middle-east)
- [Biotech Investors in Israel](https://shizune.co/investors/biotech-investors-israel)

## FAQ

### What does FutuRx invest in?

FutuRx invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Seed and Funding Round stage. Most of the 5 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact FutuRx?

Public channels for FutuRx include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at FutuRx?

The team at FutuRx includes KINNERET SAVITSKY (Chief Executive Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co